Pegvaliase statistically significantly lowered blood Phe levels in adolescents with PKU compared with diet alone. Topline data were announced from a phase 3 trial evaluating pegvaliase-pqpz in ...
On Saturday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released new Phase 3 PEGASUS study results on Saturday. The data show that its therapy Palynziq (pegvaliase-pqpz) significantly reduced blood ...
BioMarin Pharmaceutical is continuing to slim down its pipeline, this time ending work on a preclinical phenylketonuria (PKU) drug once touted as a potential successor to its approved med Palynziq.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback